AG
EIGR

Advisor Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Advisor Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2
Closed -$1K – 5397
2019
Q1 		$1K Hold
2
– – ﹤0.01% 5136
2018
Q4 		$1K Buy
+2
New +$646 ﹤0.01% 5025

Other funds holding EIGR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Advisor Group's EIGR Position: Q2 2019 in Review

Advisor Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2019, closing a stake of 2 shares — an estimated $1K sold.

Advisor Group first reported a position in EIGR in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 78 funds tracked by Wall St. Rank hold EIGR as of Q2 2019.

  • Advisor Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Advisor Group sold 2 Eiger BioPharmaceuticals, Inc. shares in Q2 2019, an estimated $1K.
  • Advisor Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
  • Advisor Group's Eiger BioPharmaceuticals, Inc. position peaked at $1K in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2019.

Based on Advisor Group's 13F filing for Q2 2019, filed 31 Jul 2019.